Pfizer publishs discovery of MEK inhibitors CI-1040 and PD 0325901

Pfizer have published data on the discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901

Pfizer have published a series of PYK2 inhibitors

Pfizer have published a series of trifluoromethylpyrimidine proline-rich tyrosine kinase 2 (PYK2) inhibitors

Pfizer to present data on JAK-inhibitor CP-690,550 at ACR meeting

Pfizer will be presenting Phase 2b data on investigational JAK-inhibitor CP-690,550 at the forthcoming ACR meeting:

Pfizer publish series of MEK inhibitors

Pfizer have publsihed a series of MEK (MAP ERK Kinase) inhibitors.

Pfizer ATM inhibitor CP466722 effective in sensitizing cells to irradiation

Treatment of cells with Pfizer’s ATM inhibitor CP466722 sensitized them to irradiation

Pfizers IGF-1R MAb CP-751,871 effective in NSCLC

Phase II data presented at the European of Medical Oncology (ESMO) show that Pfizer’s IGF-1R inhibitor CP-751,871 shows efficacy in patients with non-small cell lung cancer (NSCLC).

Sunitinib and Sorafenib cause Erythrocytosis, Indicative of class effect?

Researchers report that the development of reversible erythrocytosis is a common side effect following the use of sorafenib and sunitiniband may be a class specific adverse effect with all kinase inhibitors

NICE recommends against Avastin, Nexavar, Sutent and Torisel for Kidney Cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has made a preliminary ruling stating that Avastin, Nexavar, Sutent and Torisel  are not  effective enough to warrant their high cost and shouldn’t be prescribed to new patients in Britain.

Genentech halt Avastin/Sutent trial following cases of microangiopathic hemolytic anemia (MAHA)

Genentech have halted its trial of Avastin in combination with Sutent following reports of several cases of microangiopathic hemolytic anemia (MAHA) in patients with solid tumors

Sunitinib shows efficacy in the treatment of Advanced Neuroendocrine Tumors

Sunitinib has shown efficacy in a phase II study of pancreatic neuroendocrine tumor patients.